Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Income from Continuing Operations (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Income from Continuing Operations for 16 consecutive years, with 52698000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations fell 5.79% year-over-year to 52698000.0, compared with a TTM value of 214326000.0 through Dec 2025, up 30.78%, and an annual FY2025 reading of 214326000.0, up 30.78% over the prior year.
  • Income from Continuing Operations was 52698000.0 for Q4 2025 at Catalyst Pharmaceuticals, roughly flat from 52783000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 56737000.0 in Q1 2025 and bottomed at 30764000.0 in Q3 2023.
  • Average Income from Continuing Operations over 5 years is 28607200.0, with a median of 26421500.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations surged 364.43% in 2022, then plummeted 235.24% in 2023.
  • Year by year, Income from Continuing Operations stood at 9309000.0 in 2021, then soared by 364.43% to 43234000.0 in 2022, then plummeted by 60.59% to 17039000.0 in 2023, then skyrocketed by 228.28% to 55936000.0 in 2024, then decreased by 5.79% to 52698000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for CPRX at 52698000.0 in Q4 2025, 52783000.0 in Q3 2025, and 52108000.0 in Q2 2025.